Nine By Blue

Nine By Blue is a digital health company that has positioned itself at the intersection of AI-driven healthcare solutions and chronic disease management.

Reviewed by 7wData
Share Email

On this page

Profile

Provides AI-driven digital health solutions for chronic disease management.

Nine By Blue is a digital health company that has positioned itself at the intersection of AI-driven healthcare solutions and chronic disease management. Founded in the early 2020s, the company has evolved from a niche player into a broader platform, leveraging proprietary AI to enhance patient engagement and clinical outcomes. Its product portfolio includes AI-powered tools for chronic condition management, with a focus on diabetes and hypertension.

The company has faced challenges in scaling its commercial operations, as evidenced by its recent financials, which show a net loss of $427,000 for the first nine months of fiscal 2026. Despite this, Nine By Blue has secured partnerships with major healthcare providers and payers, expanding its reach to over 116 million covered lives through collaborations with Solera and Amwell. The company’s recent pivot toward claims-based and outcomes-driven payments reflects a strategic shift to align with value-based care models. What’s notable now is its emphasis on DarioIQ™, an AI layer that processes 13 billion real-world data points, showing promising results in member retention and engagement.

Track Nine By Blue and 240+ vendors.

48k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Healthcare payers seeking value-based care solutions
  • Employers offering wellness programs
  • Pharmaceutical companies integrating digital therapeutics
  • Hospital systems focusing on chronic care management
  • Patients with chronic conditions like diabetes and hypertension

Strengths and what to watch

Strengths

  • Proprietary AI platform (DarioIQ™) with 13 billion real-world data points
  • Access to over 116 million covered lives through channel partnerships
  • Strong clinical validation with more than 100 peer-reviewed studies

Watch for

  • Net losses persist, with a $427,000 loss in the first nine months of fiscal 2026
  • Dependence on channel partners for market access could limit direct control
  • Competitive pressure from larger digital health players entering the chronic care space

Recent moves

Key Information

Founded
2020

Frequently Asked Questions

What does Nine By Blue do?

Nine By Blue provides AI-driven digital health solutions focused on chronic disease management. Their tools help manage conditions like diabetes and hypertension, leveraging proprietary AI to improve patient engagement and clinical outcomes. The company partners with healthcare payers, employers, and pharmaceutical companies.

How does Nine By Blue use AI in healthcare?

Nine By Blue uses its proprietary AI platform, DarioIQ™, to process 13 billion real-world data points. This AI layer enhances chronic disease management by improving patient engagement and retention, particularly for conditions like diabetes and hypertension.

What is DarioIQ™?

DarioIQ™ is Nine By Blue’s AI platform that processes 13 billion real-world data points. It focuses on improving chronic disease management, particularly for diabetes and hypertension, by enhancing patient engagement and retention through advanced AI-driven insights.

What are Nine By Blue’s financial challenges?

Nine By Blue reported a net loss of $427,000 for the first nine months of fiscal 2026. Despite this, the company continues to expand its partnerships and market reach, focusing on value-based care models to improve its financial performance.

Who are Nine By Blue’s partners?

Nine By Blue partners with major healthcare providers and payers, including Solera and Amwell. These collaborations have expanded its reach to over 116 million covered lives, enabling broader access to its AI-driven chronic disease management solutions.

Is Nine By Blue’s AI clinically validated?

Yes, Nine By Blue’s AI solutions are backed by strong clinical validation, with over 100 peer-reviewed studies supporting their effectiveness. The DarioIQ™ platform, in particular, has shown promising results in improving patient engagement and chronic disease management outcomes.

Sources

  1. www.prnewswire.com — Financial results and operational updates for Q1 2026
  2. techcrunch.com — Context on AI-driven workforce shifts in tech
  3. techcrunch.com — Industry trend of AI-focused restructuring
  4. techcrunch.com — Broader market shift toward AI talent